Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Imugene Limited
  6. News
  7. Summary
    IMU   AU000000IMU9

IMUGENE LIMITED

(IMU)
  Report
Delayed Australian Stock Exchange  -  12:10 2022-11-28 am EST
0.1750 AUD   -2.78%
11/11Imugene Advances Phase 1 Metastatic Cancer Trial
MT
11/10Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA
CI
11/10Imugene's onCARlytics combination with Celularity's placental-derived off-the-shelf allogeneic CYCART-19 T cells preclinical data presented at SITC Annual Meeting
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Imugene Names Chief Medical Officer; Shares Rise 3%

10/03/2022 | 08:37pm EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
IMUGENE LIMITED -2.78% 0.175 Delayed Quote.-55.00%
NOVARTIS AG 0.36% 83.33 Delayed Quote.3.43%
ONCOLYTICS BIOTECH INC. 2.36% 2.17 Delayed Quote.21.14%
All news about IMUGENE LIMITED
11/11Imugene Advances Phase 1 Metastatic Cancer Trial
MT
11/10Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA
CI
11/10Imugene's onCARlytics combination with Celularity's placental-derived off-the-shelf all..
AQ
11/10Imugene’s on CARlytics Combination with Celularity’s Placental-derived off-th..
CI
11/01Imugene Doses First Intratumoral Patient in Phase 1 Cancer Trial
MT
10/30Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2
CI
10/18ABL and Imugene Partner to Advance Oncolytic Virus Candidate Towards Later Phase Clinic..
CI
10/07Imugene's Oncolytic Virus Technology to be Featured in Society for Immunotherapy of Can..
MT
10/03Imugene Names Chief Medical Officer; Shares Rise 3%
MT
10/03Imugene Limited Appoints Giovanni Selvaggi as Chief Medical Officer
CI
More news
Financials
Sales 2023 6,00 M 4,05 M 4,05 M
Net income 2023 -46,8 M -31,5 M -31,5 M
Net Debt 2023 - - -
P/E ratio 2023 -19,4x
Yield 2023 -
Capitalization 1 117 M 754 M 754 M
Capi. / Sales 2023 186x
Capi. / Sales 2024 107x
Nbr of Employees 5
Free-Float 91,5%
Chart IMUGENE LIMITED
Duration : Period :
Imugene Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMUGENE LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,18 AUD
Average target price 0,51 AUD
Spread / Average Target 191%
EPS Revisions
Managers and Directors
Leslie Chong Chief Executive Officer, Director & MD
Michael Tonroe Chief Financial Officer
Paul A. Hopper Executive Chairman
Nicholas Ede Chief Technology Officer
Sharon Yavrom Executive Director-Clinical Scientist
Sector and Competitors
1st jan.Capi. (M$)
IMUGENE LIMITED-55.00%775
MODERNA, INC.-30.55%67 769
IQVIA HOLDINGS INC.-22.03%40 859
LONZA GROUP AG-33.93%39 445
ALNYLAM PHARMACEUTICALS, INC.25.44%26 171
SEAGEN INC.-20.16%22 918